By Sumeet Chatterjee and Kaustubh Kulkarni MUMBAI (Reuters) - India's Sun Pharmaceutical Industries Ltd is in talks to buy Sweden's Meda AB for between $5 billion and $6 billion to boost its generics business in developed markets, two sources with direct knowledge of the process said. Meda makes specialty products, over-the-counter drugs and branded generics - the same areas of focus as Sun. The Swedish company had sales of about 13 billion crowns ($2 billion) in 2012 and has a stock market value of roughly $4 billion. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment